A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2015
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 10 Jun 2017 Biomarkers information updated
- 18 Mar 2014 According to the CliniclTrials.gov record, status changed from active, no longer recruiting to completed.
- 19 Nov 2013 Planned end date changed from 1 May 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.